Budget Impact of Aripiprazole 2-Month Ready to Use Long-Acting Injectable for Adult Patients with Schizophrenia in the United States

Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance monotherapy for bipolar I disorder (BP-I) in adults (>=18 years). This budget impact (BI) model examines the financial impact of introducing ARI 2M RTU into the existing treatment paradigm for adults with schizophrenia (SCZ) (new versus current treatment paradigm). Methods The BI model includes a hypothetical health plan cohort of 1,000,000 adult patients (≥ 18 years old) with SCZ (defined by DSM-5 criteria) eligible for treatment (Nf11,000). Wholesale acquisition cost (WAC) for currently prescribed treatments, expected WAC for ARI 2M RTU, and administration costs for each treatment over a 3-year period (base case) and changes in market shares were used to estimate the BI of the launch of ARI 2MRTU. Results The total BI of ARI 2MRTU for patients with SCZ results in savings of $108,484 over 3 years. The per-member-per-month (PMPM) savings is $0.0090 and per treated member per month savings is $1.37. Sensitivity analyses support the findings with respect to the BI, with and without ARI 2M RTU. Conclusions The introduction of ARI 2MRTU as treatment for adults with SCZ is expected to result in cost savings for health plans in the US. This is mainly due to lower cumulative acquisition costs, and to a lesser extent lower administration costs, for the new treatment mix compared to the current treatment mix.Short Description: The purpose of this budget impact analysis was to examine payer's financial consequences from Aripiprazole 2-Month Ready to Use (ARI 2M RTU) Long-Acting Injectable for Adult Patients with schizophrenia (SCZ) entering the market in the United States (US). Our results suggest that the introduction of ARI 2MRTU as treatment for adults with SCZ is expected to result in cost savings for health plans in the US.Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development & Commercialization, Inc.